UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study

European journal of cancer (1990), 2024-10, p.115078, Article 115078

2024

Volltextzugriff (PDF)

Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer

Future oncology (London, England), 2024-09, Vol.20 (29), p.1-2135

2024

Volltextzugriff (PDF)

Impact of electrostatic crosstalk on spin qubits in dense CMOS quantum dot arrays

Physical review. B, 2024-09, Vol.110 (12), Article 125414

2024

Volltextzugriff (PDF)

Infectivity of Plasmodium parasites to Aedes aegypti and Anopheles stephensi mosquitoes maintained on blood-free meals of SkitoSnack

Parasites & vectors, 2024-07, Vol.17 (1), p.290-15, Article 290

2024

Volltextzugriff (PDF)

Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Nature medicine, 2024-05, Vol.30 (5), p.1505-1505

2024

Volltextzugriff (PDF)

MP61-06 SURVIVIN AND KI-67 EXPRESSION IN PENILE SQUAMOUS CELL CARCINOMA: CLINICOPATHOLOGICAL FEATURES AND OUTCOMES

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Volltextzugriff (PDF)

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study

Cancer Immunology, Immunotherapy : CII, 2024-04, Vol.73 (6), p.106-106, Article 106

2024

Volltextzugriff (PDF)

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

The New England journal of medicine, 2024-04, Vol.390 (15), p.1359-1371

2024

Volltextzugriff (PDF)

Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update

Journal of cancer research and clinical oncology, 2024-04, Vol.150 (4), p.183-183, Article 183

2024

Volltextzugriff (PDF)

Abstract CT018: TMPRSS2-ERG and RB1 as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.CT018-CT018

2024

Volltextzugriff (PDF)

Abstract CT231: Identification of a novel agnostic predictive multiomic signature via Elastic Net/Machine Learning in TALAPRO-2 (TP-2), a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.CT231-CT231

2024

Volltextzugriff (PDF)

Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer

Cancer epidemiology, biomarkers & prevention, 2024-03, Vol.33 (3), p.419-425

2024

Volltextzugriff (PDF)

Exploratory analyses of homologous recombination repair (HRR) gene subgroups and potential associations with secondary efficacy endpoints in the HRR-deficient population from TALAPRO-2

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.178-178

2024

Volltextzugriff (PDF)

Molecular characterization of metastatic penile carcinoma (mPC) in developing countries and its association with clinical outcomes: LACOG 2018 FOUNDATION translational trial

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.10-10

2024

Volltextzugriff (PDF)

Post hoc analysis of rPFS and OS from the TALAPRO-2 (TP-2) study: Genomic subgroups based on likelihood of BRCA or HRR gene alteration status

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.136-136

2024

Volltextzugriff (PDF)

Patient-reported outcomes (PROs) with talazoparib (TALA) plus enzalutamide (ENZA) vs. placebo (PBO) plus ENZA in men with metastatic castration-resistant prostate cancer (mCRPC): Subgroup analysis of patients with novel hormonal therapy (NHT) pretreatment in the TALAPRO-2 study

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.116-116

2024

Volltextzugriff (PDF)

Patient reported outcomes (PROs) among patients with metastatic castration-resistant prostate cancer (mCRPC) by homologous recombination repair mutations (HRRm) gene clusters: Findings from the phase 3 TALAPRO-2 study cohort 2

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.109-109

2024

Volltextzugriff (PDF)

Circulating tumor cells as a predictor and prognostic tool for metastatic clear cell renal carcinoma: An immunocytochemistry and genomic analysis

Pathology, research and practice, 2024-01, Vol.253, p.154918-154918, Article 154918

2024

Volltextzugriff (PDF)

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Nature medicine, 2024, Vol.30 (1), p.257-264

2024

Volltextzugriff (PDF)

Germline EGFR Mutations and Familial Lung Cancer

Journal of clinical oncology, 2023-12, Vol.41 (34), p.5274-5284

2023

Volltextzugriff (PDF)

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study

Cancer Immunology, Immunotherapy, 2023-11, Vol.72 (11), p.3665-3682

2023

Volltextzugriff (PDF)

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

The Lancet (British edition), 2023-07, Vol.402 (10398), p.291-303

2023

Volltextzugriff (PDF)

Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5053-5053

2023

Volltextzugriff (PDF)

Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5013-5013

2023

Volltextzugriff (PDF)

1 – 25 von 190

Suche als RSS-Feed

Aktive Filter

KollektionWiley Online Library

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(180)
Mit Volltextzugriff
(162)

Publikationsform

Sprache

Englisch
(190)

Erscheinungsjahr

n.n

Thema

Science & Technology
(111)
Experiment
(67)
Particle Physics
(67)
Physics
(64)
Life Sciences & Biomedicine
(60)
High Energy Physics - Experiment
(48)
Humans
(48)
Physical Sciences
(48)
Astronomy & Astrophysics
(46)
Physics, Nuclear
(46)
Physics, Particles & Fields
(46)
Oncology
(45)
Male
(28)
Female
(21)
Middle Aged
(18)
Aged
(16)
Exact Sciences And Technology
(16)
Prognosis
(16)
Renal Cell Carcinoma
(16)
Carcinoma, Renal Cell - Drug Therapy
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study

Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer

Impact of electrostatic crosstalk on spin qubits in dense CMOS quantum dot arrays

Infectivity of Plasmodium parasites to Aedes aegypti and Anopheles stephensi mosquitoes maintained on blood-free meals of SkitoSnack

Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy

Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

MP61-06 SURVIVIN AND KI-67 EXPRESSION IN PENILE SQUAMOUS CELL CARCINOMA: CLINICOPATHOLOGICAL FEATURES AND OUTCOMES

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update

Abstract CT018: TMPRSS2-ERG and RB1 as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer

Exploratory analyses of homologous recombination repair (HRR) gene subgroups and potential associations with secondary efficacy endpoints in the HRR-deficient population from TALAPRO-2

Molecular characterization of metastatic penile carcinoma (mPC) in developing countries and its association with clinical outcomes: LACOG 2018 FOUNDATION translational trial

Post hoc analysis of rPFS and OS from the TALAPRO-2 (TP-2) study: Genomic subgroups based on likelihood of BRCA or HRR gene alteration status

Patient-reported outcomes (PROs) with talazoparib (TALA) plus enzalutamide (ENZA) vs. placebo (PBO) plus ENZA in men with metastatic castration-resistant prostate cancer (mCRPC): Subgroup analysis of patients with novel hormonal therapy (NHT) pretreatment in the TALAPRO-2 study

Patient reported outcomes (PROs) among patients with metastatic castration-resistant prostate cancer (mCRPC) by homologous recombination repair mutations (HRRm) gene clusters: Findings from the phase 3 TALAPRO-2 study cohort 2

Circulating tumor cells as a predictor and prognostic tool for metastatic clear cell renal carcinoma: An immunocytochemistry and genomic analysis

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Germline EGFR Mutations and Familial Lung Cancer

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study

Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2)

Aktive Filter

Suchergebnisse filtern